Netherlands-based IMCD has agreed to acquire Daoqin Biological Technology (Shanghai) and its affiliates to enhance its life science business in China.
The financial terms of the deal were not disclosed.
The acquisition includes Longyu International Trade (Shanghai) and Long’en Biotechnology (Guangzhou).
Founded in 2011, Daoqin specialises in functional nutrition, nutraceutical, and food ingredient distribution in China.
The company partners with suppliers and provides solutions through its technical team and laboratory.
Daoqin serves customers across the food, personal care, and pharmaceutical sectors.
Headquartered in Shanghai, Daoqin generated €16m in revenue in 2023, with a team of 21 employees.
Daoqin general manager Jack Ning said: “The Daoqin team is excited to join IMCD, as we believe there are strong synergies between our businesses and capabilities.
“By leveraging IMCD’s exceptional global network and resources, we look forward to bringing greater innovation and value to customers in the life sciences markets in China.”
IMCD specialises in the sales, marketing, and distribution of speciality chemicals and food ingredients.
Its product portfolio covers areas such as pharmaceuticals, personal care, coatings, food and nutrition, lubricants, plastics, agrochemicals, textiles, water treatment, and others.
IMCD operates a global supply chain with local warehouses, offering value-added services like repacking, dilution, and blending.
Last month, the Dutch firm successfully raised approximately €300m through an accelerated bookbuilding offering of new ordinary shares.
IMCD China managing director Nicky Huang said: “The addition of Daoqin marks another step in our journey to deepen our presence in the food and nutrition markets and broadens the scope of our life science business portfolio.
“With the acquisition of Daoqin, we are very excited to welcome a very engaged and talented team and leverage our complementary portfolios and technical expertise to enhance our capabilities and offering in the local market.”
The transaction is subject to customary closing conditions and is expected to close in Q2 2025.
